|Bid||291.30 x 900|
|Ask||291.35 x 800|
|Day's Range||289.99 - 294.53|
|52 Week Range||208.34 - 305.45|
|Beta (3Y Monthly)||1.21|
|PE Ratio (TTM)||37.26|
|Earnings Date||Jul 24, 2019|
|Forward Dividend & Yield||0.76 (0.26%)|
|1y Target Est||301.63|
Within Covance Drug Development, LabCorp (LH) is focused on driving profitable growth through expanded solutions and enhanced operational capabilities.
STMicroelectronics' (STM) Q2 results are likely to gain from robust products & solid execution. Uncertainty in some of the end-markets served and the ongoing U.S.-China trade war pose serious threats.
Alphabet's (GOOGL) focus on artificial intelligence and cloud is likely to boost second-quarter results. However, higher expenses and litigation charges are headwinds.
Solid global demand, substantial impact from the electron microscopy business and robust volume growth and productivity are likely to favor Thermo Fisher's (TMO) analytical instruments revenues.
Growth in software solutions is likely to aid F5 Networks' (FFIV) third-quarter fiscal 2019 results. However, slowdown in systems business is a persistent downside.
TE Connectivity's (TEL) industrial and communications solutions portfolio is likely to aid fiscal Q3 results. Yet, weak market conditions in China & softness in European Auto may mar top-line growth.
Quest Diagnostics' (DGX) frequent partnership wins with health care leaders and sensible buyouts are creating bountiful opportunities for the top and the bottom line.
In-vitro Diagnostics has successfully proven itself to be the best diagnostic procedures. So, investors can add stocks from this space to their watchlist.
We do not expect Texas Instruments (TXN) to perform well in Q2 owing to weakness in demand and an uncertain macro environment. However, strength in analog & embedded markets might aid results.
Abbott (ABT) registers strong Cardiovascular and Neuromodulation sales on double-digit growth in Electrophysiology, Heart Failure and Structural Heart.
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll look at Thermo Fisher...
The Zacks Analyst Blog Highlights: Northrop Grumman, Thermo Fisher Scientific, Newmont Goldcorp, Starbucks and CME
Fed's rate cut will not only make cheaper funds available to businesses and stock market investors, but also U.S. dollar less expensive in the international market.
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Analyst Blog Highlights: JPMorgan, Thermo Fisher, Broadcom, Marriott and Global Payments
The Anatomical Pathology business of Thermo Fisher (TMO) belongs to its Specialty Diagnostics segment that serves customers across healthcare and clinical laboratories.
Let's talk about the popular Thermo Fisher Scientific Inc. (NYSE:TMO). The company's shares saw a double-digit share...